SCHEMBL1406065

SCHEMBL1406065

Cc1ccc2[nH]nc(C(=O)O)c2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 7/20 0.61
MAPK1 P28482 3/20 0.61
MAPKAPK3 Q16644 3/20 0.61
MAPK6 Q16659 3/20 0.61
PRKAG1 P54619 6/20 0.58
PRKAA1 Q13131 6/20 0.58
PRKAB1 Q9Y478 6/20 0.58
HAO1 Q9UJM8 2/20 0.54
MAPKAPK2 P49137 2/20 0.52
MAPKAPK5 Q8IW41 2/20 0.52
PRKAB2 O43741 5/20 0.48
PRKAA2 P54646 5/20 0.48
PRKAG3 Q9UGI9 5/20 0.48
PRKAG2 Q9UGJ0 5/20 0.48
FLT3 P36888 2/20 0.46
MAP4K1 Q92918 1/20 0.46
GSK3B P49841 1/20 0.45
CTNNB1 P35222 1/20 0.45
WNT3A P56704 1/20 0.45
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12090187 0.86 MAPK1 (0.50) MAP2K4MAPK1MAPKAPK3MAPK6PRKAG1
SCHEMBL18967793 0.86 MAP2K4 (0.54) MAP2K4MAPK1MAPKAPK3MAPK6PRKAG1
SCHEMBL15942818 0.85 MAP2K4 (0.62) MAP2K4MAPK1MAPKAPK3MAPK6PRKAG1
SCHEMBL23432094 0.82 MAP2K4 (0.50) MAP2K4MAPK1MAPKAPK3MAPK6PRKAG1
SCHEMBL15942803 0.82 YTHDC1 (0.65) MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2
SCHEMBL4793050 0.82 KDM4E (0.65) MAP2K4MAPK1MAPKAPK3MAPK6PRKAG1
SCHEMBL20207312 0.81 HDAC3 (0.54) MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2
SCHEMBL4008217 0.81 PRKAG1 (0.56) PRKAG1PRKAA1PRKAB1HAO1PRKAB2
SCHEMBL1963463 0.81 PRKAG1 (0.56) PRKAG1PRKAA1PRKAB1HAO1PRKAB2
SCHEMBL14792020 0.81 PRKAG1 (0.56) PRKAG1PRKAA1PRKAB1HAO1PRKAB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9486892-B2 Polishing composition FUJIMI INCORPORATED (JP) 2016-11-08 US claimed
US-20060135589-A1 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors ASTEX TECHNOLOGY, INC. (GB) 2006-06-22 US claimed
JP-2006500348-A 2006-01-05 JP claimed
EP-1534685-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS Astex Technology Limited (GB) 2005-06-01 EP claimed
WO-2004014864-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS ASTEX TECHNOLOGY LIMITED (GB) 2004-02-19 WO claimed
US-20250189895-A1 METHOD OF MANUFACTURING PLATED ARTICLE TOKYO OHKA KOGYO CO., LTD. (JP) 2025-06-12 US disclosed
WO-2025106383-A1 PYRROLIDINYL DERIVATIVES USEFUL AS HCN1/HCN 2 MODULATORS MERCK SHARP & DOHME LLC (US) 2025-05-22 WO disclosed
CN-118829948-A Method for manufacturing plating shaped article 东京应化工业株式会社 2024-10-22 CN disclosed
US-20240254089-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS INCYTE CORPORATION 2024-08-01 US disclosed
CN-115819424-B Indazole quinoxaline derivative, and synthetic method and application thereof 重庆文理学院 2024-06-04 CN disclosed
WO-2024109642-A1 USE OF BENZOAZACYCLIC COMPOUND AS ALLOSTERIC MODULATOR OF β2-ADRENOCEPTOR 常州大学 2024-05-30 WO disclosed
US-11992914-B2 Polishing composition, polishing method, and method for producing substrate FUJIMI INCORPORATED (JP) 2024-05-28 US disclosed
EP-1534685-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS Astex Technology Limited (GB) 2005-06-01 EP disclosed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 US disclosed
WO-2004101548-A1 INDAZOLE HAVING ANALGESIC ACTIVITY , AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2004-11-25 WO disclosed
WO-2004074275-A1 INDAZOLAMIDES WITH ANALGESIC ACTIVITY AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) 2004-09-02 WO disclosed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 EP disclosed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 US disclosed
WO-2004014864-A1 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS ASTEX TECHNOLOGY LIMITED (GB) 2004-02-19 WO disclosed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A MAP2K4 376/4885MAPK1 23/4885MAPKAPK3 88/4885
US-20240254089-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS MRGPRX4, MRGPRX1, MRGPRX2 MAP2K4 1961/4885MAPK1 1705/4885MAPKAPK3 1298/4885
US-20060135589-A1 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors CCNC, CDK1, CDK7 MAP2K4 498/4885MAPK1 375/4885MAPKAPK3 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.